일본의 면역형광 어세이 시장 평가 : 제품별, 유형별, 용도별, 최종 사용자별, 지역별, 기회 및 예측(2018-2032년)

Japan immunofluorescence assays market is projected to witness a CAGR of 5.67% during the forecast period FY2025-FY2032, growing from USD 301.85 million in FY2024 to USD 469.13 million in FY2032. The market's growth is bolstered by the rapid expansion of the aging population, increasing investments towards enhancing the healthcare sector, and the growing prevalence of chronic and infectious diseases. The increasing focus of the government of Japan towards the improvement of the healthcare infrastructure coupled with the increasing investments are also expected to support the market growth of Japan's immunofluorescence assays.

The growing threat of cardiovascular, infectious, and autoimmune diseases is one of the major factors boosting the Japan immunofluorescence assays market size. According to a study published in the Journal of Clinical Rheumatology (JCR) in March 2024, the relative risk of autoimmune diseases, such as multiple sclerosis, Graves' disease (GD) and Hashimoto's thyroiditis (HT), and rheumatoid arthritis (RA), in Japan was 2.32. Immunofluorescence assays play a crucial role in monitoring the progression of the diseases, research and development activities, early diagnosis and detection of diseases, and effective progression of public health initiatives. Moreover, strategic collaboration between leading players of the market and major pharmaceutical companies to bolster the availability of novel diagnostic solutions further provides lucrative growth opportunities to the market.

Additionally, immunofluorescence assays are also deployed for quality control of biopharmaceutical products, including vaccines and monoclonal antibodies to ensure proper assembly, function, and folding of proteins. Such diverse applications of immunofluorescence assays are expected to bolster the country's market demand in the coming years.

Rapid Expansion of the Aging Population Bolsters Market's Demand

The increasing requirement for immunofluorescence assays can be attributed to the rapid growth of the molecular biology and immunology sectors because of rising investments towards the development of personalized and age-related healthcare diagnostic and treatment solutions. As per the estimates of the World Economic Forum, more than one in ten people in Japan are eighty or older as of September 2023. As the population ages, it becomes more prone to various diseases and disorders, augmenting the requirement for various diagnostic tools and techniques to ensure that the conditions are detected in a time-efficient manner and the patients receive adequate care. Additionally, the older population also requires frequent visits to doctors and health checkups to ensure the proper functioning of all the organs, further augmenting the requirement for immunofluorescence assays.

Increasing Investments in the Healthcare Industry Supports Market Expansion

The government of Japan is adopting a multifaceted approach to increase the country's contribution to the global healthcare industry, support the digital transformation of the healthcare sector, and enhance the healthcare services provided to the patient population. Increasing investments in technological innovations in medical technologies are aiding in improving the specificity and sensitivity of immunofluorescence assays, increasing their reliability for the detection of low-abundance biomarkers. The Japanese government is expected to hasten the implementation of digital health technologies in response to challenges such as an ageing population and rising healthcare costs. These include solutions such as telemedicine, electronic health records, and AI-driven diagnostics.

Notably, partnerships are emerging to enhance these digital integrations. For instance, a joint venture between SoftBank Group Corp. and Tempus AI, Inc., initiated in June 2024, aimed at developing personalized treatments and clinical trial recommendations. Such activities showcase the government's efforts to enhance the growth and development of the country's healthcare and research sectors and are expected to positively influence the expansion of the Japan immunofluorescence assays market.

Pharmaceutical and Biotechnology Companies Boost Market Expansion

Increasing investments towards pharmaceutical and biotechnology companies is expected to bolster Japan immunofluorescence assays market demand. Immunofluorescence assays play a crucial role in the identification of biomarkers, drug development and discovery, toxicology studies, and quality control activities. Several biotechnology and pharmaceutical companies in the country are engaging in partnerships and collaborations with leading research and academic institutions to bolster the development and availability of novel therapeutic and diagnostic solutions, augmenting the reliance on immunofluorescence assays.

According to the estimates of the Japan Pharmaceutical Manufacturers Association's Data Book for 2024, the ethical drug market in Japan grew from USD 60.6 billion in 2003 to USD 84.23 billion in 2022. Additionally, the growing preference for precision medicine that often requires precise and accurate diagnostic solutions including immunofluorescence assays is also expected to bolster the dependency upon the market.

Cancer Expected to Witness Significant Growth

The rising threat of cancer in the country is propelling the market's demand. As per the estimates of the Organization for Economic Cooperation and Development, one in three premature deaths in Japan will be caused because of cancer between 2023 and 2050. The increasing prevalence of such chronic conditions in the country is propelling the demand for advanced diagnostic solutions for reducing mortality rates by ensuring timely intervention for effective management and treatment of the conditions.

Modern immunofluorescence assays detect various biomarkers simultaneously and ensure the provision of a comprehensive view of the tumors. This capability is especially useful in the field of cancer diagnostics and research as it allows for a detailed analysis of different complex biological samples. Additionally, immunofluorescence assays are also essential for cancer research as they allow researchers to study the localization and expression of proteins within the cancer cells.

Future Market Scenario (FY2025 - FY2032F)

According to Japan immunofluorescence assays market analysis, the market is expected to observe significant growth over the forecast period due to the rapid expansion of the ageing population, the growing threat of infectious and chronic diseases, and increasing investments towards research and development activities. As per an article published in the American Association for Cancer Research (AACR), the prevalence of cancer in Japan is estimated to reach 3,665,900 by 2050.

The rapid expansion of the biotechnology industry coupled with the increasing emphasis on the enhancement of the healthcare infrastructure is also expected to provide lucrative growth opportunities to the market. With increasing requirements for early disease diagnosis and precision medicine, the reliance on immunofluorescence assays will increase significantly in Japan.

The rising efforts of the government to bolster the availability of cost-effective diagnostic solutions to ensure the affordability and accessibility of technologically advanced diagnostic tools will sustain the market's growth over the forecast period.

Key Players Landscape and Outlook

Strategic collaborations between leading scientific institutions in Japan and key players in the market to bolster the development and availability of advanced technologies in the country are providing lucrative growth opportunities to Japan immunofluorescence assays market.

In May 2023, Konica Minolta, Inc. and Japan Bio Measurement & Analysis Consortium (JMAC) announced a proposal for promoting the adoption of advanced technologies that originated in Japan. The novel standards developed along with the Ministry of Economy, Trade and Industry cover indirect immunofluorescence assays with fluorescent nanoparticles that are utilized for labelling molecules that bind to secondary antibodies, including streptavidin. The issued standards standardize the performance evaluation indicators including quantification accuracy verification guidelines, particle size, and detection sensitivity, for protein quantification kits and staining reagents, among others (Konica Minolta's phosphor-integrated dots (PID).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Immunofluorescence Assays Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Products
    • 4.2.1.1. Antibodies
      • 4.2.1.1.1. Primary Antibodies
      • 4.2.1.1.2. Secondary Antibodies
    • 4.2.1.2. Kits and Reagents
      • 4.2.1.2.1. Stains and Dyes
      • 4.2.1.2.2. Media and Sera
      • 4.2.1.2.3. Buffers and Solvents
      • 4.2.1.2.4. Probes
      • 4.2.1.2.5. Other Reagents
    • 4.2.1.3. Instruments
      • 4.2.1.3.1. Image Analysis Systems
      • 4.2.1.3.2. Microscopes
    • 4.2.1.4. Consumables and Accessories
  • 4.2.2. By Type
    • 4.2.2.1. Indirect Immunofluorescence
    • 4.2.2.2. Direct Immunofluorescence
  • 4.2.3. By Application
    • 4.2.3.1. Cancer
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Cardiovascular Diseases
    • 4.2.3.4. Autoimmune Diseases
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Academic and Research Institutes
    • 4.2.4.2. Pharmaceutical and Biotechnology Companies
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Hospitals and Diagnostic Centers
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Products
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Clinical Trials
• 12.2. Regulatory Approvals

13. Patent Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Immuno-Biological Laboratories Co, Ltd.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Euroimmun Japan Co., Ltd.
  • 15.3.3. Thermo Fisher Scientific Inc.
  • 15.3.4. Bio-Rad Laboratories, Inc.
  • 15.3.5. Abcam plc
  • 15.3.6. PerkinElmer Inc.
  • 15.3.7. Merck KGaA
  • 15.3.8. Cell Signaling Technology, Inc.
  • 15.3.9. Danaher Corporation
  • 15.3.10. Sino Biological, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer